Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer

NCT00480025 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00480025
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00480025 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Terminated
Start date
October 4, 2007
Completion date
September 23, 2014
Enrollment
2,278 (actual)
Sites
620

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, non-small cell